Alnylam Pharmaceuticals Inc (ALNY)

[surf1944]

8:05AM Alnylam Pharma presents new data from ALN-TTR Program; remain on track to report data from our Phase I trial (ALNY) 9.19 : "We are pleased with the progress we are making in our ALN-TTR program and remain on track to report data from our Phase I trial in the third quarter of this year. The new data presented at the Peripheral Nerve Society Meeting define blood levels of circulating transthyretin in ATTR patients and gene carriers, and are informative in our efforts to develop our RNAi therapeutic for this devastating disease," "In addition to progress in our ALN-TTR program, we remain on track in our other 'Alnylam 5x15(TM)' programs. Specifically, we expect to file our regulatory documents in the coming weeks to begin a Phase I trial with ALN-PCS for the treatment of severe hypercholesterolemia, and we remain on track to report human proof-of-concept data from the ALN-PCS program by year end."